Comparison of FDG and FET PET in patients with primary central nervous system lymphoma

Prospective comparison of 18F-FDG and 18F-FET PET in treatment response evaluation in patients with primary central nervous system lymphoma

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0009839

Enrollment

Registered

2024-10-11

Start date

2023-01-16

Completion date

Unknown

Last updated

2024-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : Patients who meet the enrollment criteria, including those with CNS lymphoma confirmed by surgery and biopsy or suspected based on imaging findings, and who have undergone or are sche

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Adults aged 19 years or older (2) Patients diagnosed with central nervous system lymphoma through surgery and biopsy, or those with suspected central nervous system lymphoma based on anatomical imaging such as MRI (3) Patients who have undergone or are scheduled to undergo 18F-FDG PET in the above scenarios

Exclusion criteria

Exclusion criteria: (1) Pediatric and adolescent patients under the age of 19 (2) Pregnancy and breastfeeding (3) Cases where lymphoma lesions are confirmed or suspected in organs other than the central nervous system (4) Patients who, in the investigator’s judgment, are unable to provide complete data for the clinical trial due to personal circumstances or other reasons (5) Patients with conditions such as claustrophobia, movement disorders, anxiety disorders, or seizures that prevent stable PET/CT imaging (6) Patients who, in the investigator’s judgment, have serious and/or uncontrolled and/or unstable medical conditions (e.g., congestive heart failure, acute myocardial infarction, severe pulmonary disease, chronic kidney disease, or chronic liver disease)

Design outcomes

Primary

Measure	Time frame
The treatment response will be evaluated by synthesizing and reaching a consensus on both qualitative and quantitative indicators, and then compared with the reference standard.	—

Secondary

Measure	Time frame
The treatment effect will be determined by assessing the degree of uptake in lesions compared to non-lesions and analyzing the changes in qualitative and quantitative indicators. The changes in these qualitative and quantitative indicators will be evaluated according to the PERCIST criteria.	—

Countries

Korea, Republic of

Contacts

Public ContactNa Eun Lee

Asan Medical Center

mellisa108@naver.com+82-2-3010-5690

Outcome results